Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 1:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 5,061 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Influenza
Interventions: Nitazoxanide, Oseltamivir, Placebo Oral Tablet, Placebo Oral Capsule; Drug
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 13 Years to 65 Years
Enrollment: 1,941 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 136
States / cities: Birmingham, Alabama • Dothan, Alabama • Hoover, Alabama + 121 more

Conditions: Healthy Volunteers
Interventions: GDC-0134 F09 Formulation, GDC-0134 F15 Formulation, GDC-0134 F16 Formulation; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: Traumatic Brain Injury
Interventions: Multivitamin Supplement intervention; Dietary Supplement
Lead sponsor: Amen Clinics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Functional Gastrointestinal Disorders
Interventions: Salix Probiotic Blend; Dietary Supplement
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma
Interventions: Isatuximab, Belantamab mafodotin, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: CD20-positive B-cell Non-Hodgkin Lymphoma
Interventions: Part 1, Cohort 1, Part 1, Cohort 2, Part 1, Cohort 3, Part 2, Cohort 1, Part 2, Cohort 2; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: New York, New York • Rochester, New York • Nashville, Tennessee + 1 more

Conditions: Postmenopausal Osteoporosis, Gut Microbiota, Cardiovascular Diseases
Interventions: blackcurrant (BC) extract; Drug
Lead sponsor: University of Connecticut; Other
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Colorectal Neoplasms
Interventions: E7386, Lenvatinib, Doxorubicin, Paclitaxel; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 28
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 22 more

Conditions: Acute Moderate to Severe Pain
Interventions: Q8003, Placebo; Drug
Lead sponsor: QRxPharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Anaheim, California • Pasadena, Maryland • Altoona, Pennsylvania + 2 more

Conditions: Healthy Volunteers
Interventions: NPT200-11, Placebo; Drug
Lead sponsor: Neuropore Therapies Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Hypertension
Interventions: Darusentan, Guanfacine, Darusentan Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 849 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 87
States / cities: Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 70 more

Conditions: Albuminuria, Diabetic Nephropathy
Interventions: XL784; Drug
Lead sponsor: Symphony Evolution, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 45
States / cities: Birmingham, Alabama • Haleyville, Alabama • Phoenix, Arizona + 38 more

Conditions: Recurrent Glioblastoma Multiforme(GBM)
Interventions: ACT001, ACT001 + Pembrolizumab; Drug
Lead sponsor: Accendatech USA Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Amyotrophic Lateral Sclerosis, Healthy Volunteer
Interventions: SAR443820, Erythromycin ethyl succinate, Itraconazole; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Bipolar Disorder
Interventions: Ziprasidone, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Orange City, Florida • Fayetteville, Georgia • Smyrna, Georgia + 6 more

Conditions: Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions: SEL, FIR, CILO, FENO, VAS; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 12
States / cities: Chandler, Arizona • La Jolla, California • Los Angeles, California + 7 more

Conditions: Schizophrenia, Schizo Affective Disorder
Interventions: Lumateperone, Placebo; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Aging, Lipemia
Interventions: Nicotinamide riboside chloride (Niagen), Placebo; Dietary Supplement
Lead sponsor: Iowa State University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Ames, Iowa

Conditions: Clostridium Difficile Infection
Interventions: RBX7455; Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Exercise Performance
Interventions: Recombinant Bovine Lactoferrin, Bovine Milk-Derived Lactoferrin, Placebo; Dietary Supplement
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 42 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Onychomycosis
Interventions: SUBA-itraconazole, Itraconazole, Placebo; Drug
Lead sponsor: Halcygen Pharmaceuticals Limited; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 8
States / cities: Altamonte Springs, Florida • Miami, Florida • Boise, Idaho + 5 more

Conditions: Prostatic Neoplasms
Interventions: Pembrolizumab, Olaparib, Abiraterone acetate, Prednisone, Enzalutamide, Prednisolone; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 793 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 29
States / cities: Fullerton, California • Los Angeles, California • Washington D.C., District of Columbia + 24 more

Conditions: Chronic Kidney Disease, Anemia
Interventions: Roxadustat, Placebo; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 34
States / cities: Peoria, Arizona • Tempe, Arizona • Los Angeles, California + 31 more

Conditions: Sarcopenia, Gait Disorders in Old Age, Muscle Weakness
Interventions: BIO101, Placebo; Drug
Lead sponsor: Biophytis; Industry
Eligibility: 65 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 19
States / cities: Banning, California • Garden Grove, California • San Diego, California + 15 more

Search by objective public record fields.

Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

A Study to Determine the Bioavailability of Various Formulations of GDC-0134 in Healthy Female Participants of Non-Childbearing Potential

Single Photon Emission Computed Tomography (SPECT) Imaging Study of Professional American Football Players

A Study to Assess the Efficacy and Safety of Salix Probiotic Blend in Participants With Functional Gastrointestinal Disturbances

Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma

A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma

Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis and CVD Risk

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Extension Study to Evaluate the Safety of Q8003 in Patients With Acute Moderate to Severe Pain

Phase 1 Study of NPT200-11 in Healthy Subjects

DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension

Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy

A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)

Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder

Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)

Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia

Effects of Nicotinamide Riboside on Metabolism and Vascular Function

Treatment of Recurrent Clostridium Difficile Infection With RBX7455

Efficacy of Recombinant Bovine Lactoferrin (rbLf) in Iron Regulation

Study Comparing SUBA™-Itraconazole With SPORANOX® (Itraconazole) in the Treatment of Onychomycosis

Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis

A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT)